AI deftly reclassifies lung nodules for cancer risk

A convolutional neural network trained and internally validated on more than 15,000 lung CT scans has correctly reclassified indeterminate pulmonary nodules (IPNs) into low-risk or high-risk categories.

The AI system proved its mettle in external validation testing. Here it reclassified more than a third of nearly 600 real-world nodules, malignant and benign, with significantly better accuracy than conventional risk models with which researchers and developers compared it.

The study was conducted at Vanderbilt University and is published in full for free in the American Journal of Respiratory and Critical Care Medicine.

In their discussion section, lead author Pierre Massion, MD, and colleagues comment that their neural network’s demonstration of high performance may mean the technology has potential for changing patient management. If so, it would accomplish this mainly by obviating unnecessary invasive procedures and reducing delays in diagnosis.

Vanderbilt’s internal coverage of the development notes that adherence to current guidelines offered by the American College of Radiology and the American College of Chest Physicians can be variable, leading to subjective nodule classifications.

The present study, the school states, “is the first to validate a risk-stratification tool on multiple independent cohorts and to show reclassification performance that is significantly superior to existing risk models.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.